DelveInsight’s “Vasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vasomotor Symptoms, historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Vasomotor Symptoms market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vasomotor Symptoms Market Forecast

Some of the key facts of the Vasomotor Symptoms Market Report:

• The Vasomotor Symptoms market size was vlaued ~USD 2,100 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In January 2025, Bayer reported positive topline results from the Phase III OASIS 4 trial evaluating elinzanetant as a non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) in women undergoing adjuvant endocrine therapy for breast cancer or at high risk of the disease. The study met its primary endpoints, showing statistically significant reductions in the frequency of moderate to severe VMS from baseline to weeks 4 and 12 compared to placebo. Additionally, all secondary endpoints were achieved, including reductions in VMS severity at weeks 4 and 12, early symptom relief by week 1, and sustained efficacy throughout the study duration.

• In August 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced the dosing of the first patient in the HIGHLIGHT 1™ Phase 3 pivotal study for fezolinetant, an investigational oral, non-hormonal compound being evaluated for the treatment of moderate to severe vasomotor symptoms (VMS) in women with breast cancer undergoing adjuvant endocrine therapy.

• In May 2024, Noema Pharma AG, a clinical-stage biotech firm focused on debilitating neuroscience-related disorders, has announced that the first patient has been dosed in a Phase 2a open-label study assessing the safety and efficacy of NOE-115, a broad-spectrum monoamine modulator, in women experiencing vasomotor symptoms (VMS, commonly known as “hot flashes”) along with other menopause-related issues such as weight gain, daytime fatigue, and cognitive challenges.

• In 2023, the total prevalent cases of Vasomotor Symptoms were approximately 136 million across the 7MM, with a slight decrease anticipated by 2034 at a mild CAGR. The US reported the highest number of prevalent cases of Vasomotor Symptoms within the 7MM.

• In 2023, the prevalent cases of Vasomotor Symptoms in the EU4 and the UK were approximately 59.5 million, with an estimated decline expected by 2034 at a mild CAGR. Germany recorded the highest number of prevalent cases of Vasomotor Symptoms among the EU4 and the UK.

• According to DelveInsight’s estimates, in 2023, the highest proportion of prevalent cases of Vasomotor Symptoms in the 7MM was found in the 60–65 age group (approximately 27%), followed by the 55–59 and 50–54 age groups. The fewest cases were recorded in the 40–44 age group.

• According to our analysis, in 2023, there were approximately 41 million cases of hot flashes and about 38 million cases of night sweats in the 7MM. Of the total cases of hot flashes, around 64% were classified as mild, 22% as moderate, and 14% as severe within the 7MM.

• As per DelveInsight’s estimates, there were approximately 7.5 million treated cases of Vasomotor Symptoms in the 7MM in 2023.

• Key Vasomotor Symptoms Companies: Mithra Pharmaceuticals, Bayer/Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe Pharma, QUE Oncology, Bayer, Duramed Research, Mitsubishi Tanabe Pharma, Pfizer, Fervent Pharma, Astellas Pharma, Merck Sharp & Dohme, Que Oncology, Eli Lilly and Company, and others

• Key Vasomotor Symptoms Therapies: Donesta(E4, Estetrol), Elinzanetant (BAY-3427080, NT 814), Fezolinetant (ESN-364), MNGX-100 (Filgrastim, G-CSF), Elismetrep(MT-8554), Q-122 (MSX-122), Estetrol, Angeliq (Drospirenone/17ß-estradiol, BAY86-4891), SCE-B, MT-8554, desvenlafaxine succinate, DVS-233 SR, FP-101, Estradiol/DRSP, fezolinetant, esmirtazapine, Q-122, Raloxifene, and others

• The Vasomotor Symptoms epidemiology based on age-specific cases analyzed that Vasomotor Symptoms is most prevalent in females at an age of 60–65 years old

• The Vasomotor Symptoms market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vasomotor Symptoms pipeline products will significantly revolutionize the Vasomotor Symptoms market dynamics.

Vasomotor Symptoms Overview

Vasomotor symptoms (VMS) refer to a group of symptoms related to changes in blood vessel function, particularly in the context of hormonal fluctuations. These symptoms commonly occur during menopause but can also be experienced during other life stages or as a result of certain medical conditions or treatments.

Get a Free sample for the Vasomotor Symptoms Market Report:

https://www.delveinsight.com/report-store/vasomotor-symptoms-market

Vasomotor Symptoms Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Vasomotor Symptoms Epidemiology Segmentation:

The Vasomotor Symptoms market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Vasomotor Symptoms in the 7MM

• Total Age-specific Cases of Vasomotor Symptoms in the 7MM

• Total Severity-specific Cases of Vasomotor Symptoms in the 7MM

• Total Treated Cases of Vasomotor Symptoms in the 7MM

Download the report to understand which factors are driving Vasomotor Symptoms epidemiology trends @ Vasomotor Symptoms Epidemiology Forecast

Vasomotor Symptoms Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vasomotor Symptoms market or expected to get launched during the study period. The analysis covers Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Vasomotor Symptoms Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Vasomotor Symptoms Therapies and Key Companies

• Donesta(E4, Estetrol): Mithra Pharmaceuticals

• Elinzanetant (BAY-3427080, NT 814): Bayer/Nerre Therapeutics

• Fezolinetant (ESN-364): Astellas Pharma

• MNGX-100 (Filgrastim, G-CSF): MenoGeniX

• Elismetrep(MT-8554): Mitsubishi Tanabe Pharma

• Q-122 (MSX-122): QUE Oncology

• Estetrol: Estetra

• Angeliq (Drospirenone/17ß-estradiol, BAY86-4891): Bayer

• SCE-B: Duramed Research

• MT-8554: Mitsubishi Tanabe Pharma

• desvenlafaxine succinate: Pfizer

• DVS-233 SR: Pfizer

• FP-101: Fervent Pharma

• Estradiol/DRSP: Bayer

• fezolinetant: Astellas Pharma

• esmirtazapine: Merck Sharp & Dohme

• Q-122: Que Oncology

• Raloxifene: Eli Lilly and Company

Discover more about therapies set to grab major Vasomotor Symptoms market share @ Vasomotor Symptoms Treatment Market

Vasomotor Symptoms Market Strengths

• An increasing population of geriatric women and raising awareness about women’s hygiene, dietary habits, and stress indicators have shed light on hormonal imbalances among women.

Vasomotor Symptoms Market Opportunities

• Favorable policies initiated by the government to improve women’s health and raise awareness are likely to propel the market and drive various Pharmaceutical companies to conduct R&D activities.

Scope of the Vasomotor Symptoms Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Vasomotor Symptoms Companies: Mithra Pharmaceuticals, Bayer/Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe Pharma, QUE Oncology, Bayer, Duramed Research, Mitsubishi Tanabe Pharma, Pfizer, Fervent Pharma, Astellas Pharma, Merck Sharp & Dohme, Que Oncology, Eli Lilly and Company, and others

• Key Vasomotor Symptoms Therapies: Donesta(E4, Estetrol), Elinzanetant (BAY-3427080, NT 814), Fezolinetant (ESN-364), MNGX-100 (Filgrastim, G-CSF), Elismetrep(MT-8554), Q-122 (MSX-122), Estetrol, Angeliq (Drospirenone/17ß-estradiol, BAY86-4891), SCE-B, MT-8554, desvenlafaxine succinate, DVS-233 SR, FP-101, Estradiol/DRSP, fezolinetant, esmirtazapine, Q-122, Raloxifene, and others

• Vasomotor Symptoms Therapeutic Assessment: Vasomotor Symptoms current marketed and Vasomotor Symptoms emerging therapies

• Vasomotor Symptoms Market Dynamics: Vasomotor Symptoms market drivers and Vasomotor Symptoms market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Vasomotor Symptoms Unmet Needs, KOL’s views, Analyst’s views, Vasomotor Symptoms Market Access and Reimbursement

To know more about Vasomotor Symptoms companies working in the treatment market, visit @ Vasomotor Symptoms Clinical Trials and Therapeutic Assessment

Table of Contents

1. Vasomotor Symptoms Market Report Introduction

2. Executive Summary for Vasomotor Symptoms

3. SWOT analysis of Vasomotor Symptoms

4. Vasomotor Symptoms Patient Share (%) Overview at a Glance

5. Vasomotor Symptoms Market Overview at a Glance

6. Vasomotor Symptoms Disease Background and Overview

7. Vasomotor Symptoms Epidemiology and Patient Population

8. Country-Specific Patient Population of Vasomotor Symptoms

9. Vasomotor Symptoms Current Treatment and Medical Practices

10. Vasomotor Symptoms Unmet Needs

11. Vasomotor Symptoms Emerging Therapies

12. Vasomotor Symptoms Market Outlook

13. Country-Wise Vasomotor Symptoms Market Analysis (2020–2034)

14. Vasomotor Symptoms Market Access and Reimbursement of Therapies

15. Vasomotor Symptoms Market Drivers

16. Vasomotor Symptoms Market Barriers

17. Vasomotor Symptoms Appendix

18. Vasomotor Symptoms Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/